Scholarlink

<p>This letter highlights emerging immune-targeted therapies for immune thrombocytopenia (ITP) presented at the 2025 ASH Annual Meeting. We summarize pivotal data, including the Phase III VAYHIT2 trial of Ianalumab, alongside novel early-phase agents targeting BAFF-R, CD38, CD19, PI3K, and cellular therapies (CD19/BCMA CAR-T), which provide crucial biological insights and hypothesis-generating signals for future ITP management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月28日

查看全文
  • Linyu Cao,
  • Zhe Wang,
  • Qian Xiang

摘要

This letter highlights emerging immune-targeted therapies for immune thrombocytopenia (ITP) presented at the 2025 ASH Annual Meeting. We summarize pivotal data, including the Phase III VAYHIT2 trial of Ianalumab, alongside novel early-phase agents targeting BAFF-R, CD38, CD19, PI3K, and cellular therapies (CD19/BCMA CAR-T), which provide crucial biological insights and hypothesis-generating signals for future ITP management.